S-4066-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Josh Hawley (R-MO)
What it does
This bill would place restrictions on chemical abortion — the use of medications (typically mifepristone and misoprostol) to end a pregnancy. Based on the bill's title, it would likely impose new federal requirements or prohibitions related to the prescribing, dispensing, or distribution of abortion-inducing medications. Because the full legislative text was not provided, the precise mechanical details — such as which drugs are covered, what penalties apply, or which federal agencies would enforce the law — cannot be confirmed from the available information.
Who benefits
Individuals and organizations that oppose abortion access on moral, ethical, or religious grounds. Providers who do not offer medication abortion and may face less competitive pressure. States that have enacted abortion restrictions and seek federal alignment with those policies. Fetal life, in the view of those who hold that life begins at conception.
Who is hurt
Patients who use or seek medication abortion, particularly those in early pregnancy for whom it is the primary option. Patients in states with limited surgical abortion access who rely on medication abortion as an alternative. Telehealth providers and mail-order pharmacies that have expanded medication abortion access since the FDA's 2021 rule change. OB-GYNs and other prescribers who currently offer this option. Lower-income patients and those in rural areas who may have fewer alternatives if medication abortion is restricted.
Supporters argue
Supporters argue that medication abortion carries underreported medical risks — including incomplete abortion, hemorrhage, and infection — and that current FDA oversight and remote prescribing rules are insufficient to protect patients. They contend that in-person physician involvement and stricter dispensing controls are necessary to ensure women receive proper screening, follow-up care, and accurate information before taking these drugs, citing studies they argue show adverse event rates higher than FDA labeling reflects.
Opponents argue
Opponents argue that mifepristone has been FDA-approved for over two decades with a well-documented safety record, and that the National Academies of Sciences has found medication abortion to be safe and effective. They contend that restricting access — particularly via mail and telehealth — would disproportionately harm low-income patients and those in rural or abortion-restricted states who have no practical surgical alternative, effectively eliminating abortion access for a significant portion of the population.
Constitutional context
Congress may regulate the manufacture and distribution of drugs under the Commerce Clause (Art. I, §8, cl. 3), and the FDA's authority over drug approval and distribution rests on that foundation. Post-Dobbs (2022), abortion regulation has been returned to legislatures, but federal drug law under the Supremacy Clause (Art. VI, cl. 2) may preempt conflicting state rules — a tension that is actively being litigated. Post-Loper Bright (2024), any FDA regulatory interpretation underlying current medication abortion access rules would face independent judicial review rather than automatic deference.
Checks and balances
Congress would gain authority to restrict a federally approved drug's distribution; the FDA retains its drug approval role but its implementing regulations face heightened judicial scrutiny post-Loper Bright; courts serve as a check through ongoing litigation over both federal drug law preemption and post-Dobbs abortion authority.
Historical precedent
The Comstock Act of 1873 prohibited mailing of abortion-inducing drugs, but was not enforced for decades; its potential modern applicability to medication abortion is currently an active and unresolved legal question.